Search clinical trials for: Tapentadol IR (CG5503)

Total 394 results

Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain

Low Back Pain
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Arthritis | Joint Diseases | Osteoarthritis
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Dose-proportionality of Tapentadol (CG5503) in Healthy Japanese and Korean Male Volunteers

Healthy Volunteer
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Terminated

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety

Arthroplasty

United States, United Kingdom, Belgium, Spain, Canada, Finland, New Zealand, Sweden
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery

Osteoarthritis | Arthralgia | Pain Assessment
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 25-mg Tablets Relative to One 50-mg Tablet

Healthy Volunteer
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo Followed by a Voluntary Open Label Extension for Safety.

Arthralgia | Bunion | Hallux Valgus | Pain Assessment | Tapentadol
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet

Healthy Volunteer
Janssen Research & Development, LLC

Completed

A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy

Hallux Valgus

Korea, Republic of
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Pain | Lower Back Pain | Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Canada
Janssen-Cilag International NV
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo

Hallux Valgus

Taiwan
Ortho-McNeil Janssen Scientific Affairs, LLC
Grünenthal GmbH

Completed

Safety and Efficacy of Tapentadol Immediate Release (IR) and Oxycodone IR for Treatment of Acute Post-op Pain Following Elective Arthroscopic (Surgery Using a Thin Flexible Scope) Shoulder Surgery

Postoperative Pain
Grünenthal GmbH
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy

Hysterectomy | Postoperative

Russian Federation, Hungary, Latvia, Poland, Romania, Serbia, Slovakia, Slovenia, Ukraine
Ortho-McNeil Janssen Scientific Affairs, LLC
Grünenthal GmbH

Completed

Tapentadol IR vs Oxycodone IR vs Placebo in Acute Pain From Vertebral Compression Fracture Associated With Osteoporosis

Back Pain

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Risk of Shopping Behavior of Tapentadol Immediate-Release (IR) Compared to Oxycodone Immediate-Release (IR)

Substance Abuse Detection
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

Low Back Pain
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

Pain | Arthralgia | Bunion | Hallux Valgus

United States
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

Tapentadol (CG5503)

Pain | Osteoarthritis, Knee
Grünenthal GmbH
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy

Pain | Postoperative Pain | Acute Pain | Bunionectomy

United States
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain

Pain | Osteoarthritis | Low Back Pain

United States, Australia, Canada, New Zealand
Bioxodes S.A.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy

Diabetic Neuropathy
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain

Osteoarthritis | Arthralgia | Low Back Pain | Sciatica | Pain Intensity Assessment
University Hospital Schleswig-Holstein

Terminated

Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models

Pain | Hyperalgesia | Allodynia

Germany
Federal University of São Paulo

Unknown

Far-IR Emitted by Compression Stockings for Cellulitis Treatment

Quality of Life | Cellulitis
Grünenthal GmbH
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol)

Pharmacokinetic

Belgium
Grünenthal GmbH

Completed

Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women

Prolonged QTc Interval | Pharmacokinetic

Germany
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Melanoma | Small Cell Lung Cancer | Colorectal Neoplasms | Ovarian Neoplasms | Liposarcoma

United States
Bioxodes S.A.

Recruiting

A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage (BIRCH)

Intracerebral Hemorrhage

Belgium
IR Technology, LLC

Not yet recruiting

Clinical Trial of the invisaRED® IR REHAB Device When Used as an Adjunctive Therapy for Nociceptive Musculoskeletal Pain

Musculoskeletal Pain | Nociceptive Pain
Grünenthal GmbH

Completed

Pharmacokinetic Characterization of Two Novel CG5503 Tablet Formulations in Healthy Volunteers

Pharmacokinetics

Germany
Mayo Clinic
National Center for Research Resources (NCRR)

Completed

Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans (tap-oxy)

Effects of 2 Mu-opiates on Gastrointestinal Transit

United States
Stallergenes Greer

Completed

Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR

Rhinitis, Allergic, Perennial | House Dust Mite Allergy

France, United States
F2G Biotech GmbH
Quotient Clinical

Completed

Evaluation of Immediate Release Tablet

Invasive Aspergillosis

United Kingdom
Landos Biopharma Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

Ulcerative Colitis

United States, Ukraine
University of Rochester
National Institute of Nursing Research (NINR); Stanford University

Recruiting

Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)

Healthy Aging | Mild Cognitive Impairment

United States
Institut Pasteur de Lille
Luxomed

Terminated

Interest in the Medium Term of an Infrared Reflexotherapy on Overweight or Class I Obese People (REFLEX-IR)

Assess the Effect of an IR Reflexotherapy on Overweight and Class I Obese People

France
Bristol-Myers Squibb

Completed

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors

Neoplasms | Solid Tumors | Metastases

Australia
Cerevel Therapeutics, LLC

Recruiting

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

Healthy Participants

United States
The University of Texas Medical Branch, Galveston

Completed

Validation of a Novel Screening Test for Maternal Insulin Resistance

Insulin Resistance, Diabetes

United States
Pfizer

Completed

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Healthy Participants

Belgium
Rutgers, The State University of New Jersey

Completed

Family Presence on Multidisciplinary Patient Care Rounds in ICU

Critical Illness

United States
University of Texas Southwestern Medical Center

Completed

Infrared Imaging for Breast Cancer Modeling

Breast Cancer

United States
National Institute of Neurological Disorders and...

Completed

Infrared Camera for Brain Mapping During Surgery

Epilepsy | Neurologic Manifestations

United States
Yuhan Corporation

Completed

Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation

Functional Constipation

Korea, Republic of
Rutgers, The State University of New Jersey

Not yet recruiting

Developing and Testing a Nurse-Led Technology-Enhanced Family Engagement Program

Critical Illness

United States
MetroHealth Medical Center

Completed

SIC-IR Billing and Documentation (SIC-IR)

Medical Record Documenation | Surgical and Trauma Intensive Care Unit Billing

United States
LGD
ProRelix Services LLP

Recruiting

Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients

Sickle Cell Disease

India
Incyte Corporation

Active, not recruiting

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

Healthy Participants

United States
Janssen Research & Development, LLC

Completed

Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers

Healthy

3

Subscribe